[1] 刘丽,许艳瑾,尹伶.我国子宫肌瘤的流行病学特征[J].现代预防医学,2014,41(2):112-115.[2] D?Angelo E,Prat J.Uterine sarcomas:a review[J].Gynecol Oncol,2010,116:131-139[3] 张果,祝洪澜,魏丽惠.子宫肉瘤分类、分期及治疗进展[J].中国妇产科临床杂志,2010,15(5):397-400.[4] FDA. FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids[R].Food Drug Adm, 2014,17:4.[5] García-Martínez E,Prefasi LE,García-Donas J,et al.Current management of uterine sarcomas[J].Clin Transl Oncol,2011,13(5):307-314.[6] Wu TI,Yen TC,Lay CH.Clinical presentation and diagnosis of uterine sarcoma,including imaging[J].Best Pract Res Clin Obstet Gynaecol, 2011, 25(6):681-689.[7] Tropé CG,Abeler VM,Kristensen GB.Diagnosis and treatment of sarcoma of the uterus: a review[J].Acta Oncol, 2012, 51(6):694-705.[8] Bansal N,Herzog TJ,Burke W,et al.The utility of preoperative endometrial sampling for the detection of uterine sarcomas[J].Gynecol Oncol, 2008, 110(1):43-48.[9] Kawamura N,Ichimura T,Ito F,et al.Transcervical needle biopsy for the differential diagnosis between uterine sarcoma and leiomyoma[J].Cancer, 2002, 94(6):1713-1720.[10] Goto A,Takeuchi S,Sugimura K,et al.Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus[J].Int J Gynecol Cancer,2002, 12(4):354-361.[11] Juang CM,Yen MS,Horng HC,et al.Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma[J].Eur J Gynaecol Oncol, 2006, 27(4):370-374.[12] Exacoustos C,Romanini ME,Amadio A,et al.Can gray-scale and color Doppler sonography differentiate between uterine leiomyosarcoma and leiomyoma?[J]. Clin Ultrasound, 2007,35(8):449-457.[13] Aviram R,Ochshorn Y,Markovitch O,et al.Uterine sarcomas versus leiomyomas:gray-scale and Doppler sonographic findings[J].J Clin Ultrasound, 2005, 33(1):10-13.[14] Santos P,Cunha TM. Uterine sarcomas:clinical presentation and MRI features[J].Diagn Interv Radiol,2015,21(1):4-9.[15] Yoshida Y,Kiyono Y,Tsujikawa T,et al. Additional value of 16α-[18F]fluoro-17β-oestradiol PET for differential diagnosis between uterine sarcoma and leiomyoma in patients with positive or equivocal findings on[18F]fluorodeoxyglucose PET[J]. Eur J Nucl Med Molec Imag,2011,38(10):1824-1831.[16] Park JY,Park SK,Kim DY,et al.The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma[J].Gynecol Oncol, 2011, 122(2):255-259.[17] Cohen SL,Einarsson JI,Wang KC,et al.Morcellation within contained pneumoperitoneum:technical report and case series[J].J Minim Invas Gynec,2014,21(6):S43-S49.(2015-11-23收稿) |